Company: PRGO
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001585364-25-000056
Chunk: 213

Company: PERRIGO Co plc
Filing Date: 2025-05-07
Form: 10-Q
Item: Item 9
Chunk 213
---
NOTE 9 - FAIR VALUE MEASUREMENTS 

The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):March 29, 2025December 31, 2024Measured at fair value on a recurring basis:Level 1Level 2Level 3Level 1Level 2Level 3Assets:Foreign currency forward contracts$— $2.1 $— $— $5.5 $— Cross-currency swaps— — — — 14.2 — Interest rate swap agreements— 5.3 — — 9.3 — Total assets$— $7.4 $— $— $29.0 $— Liabilities:Foreign currency forward contracts$— $5.6 $— $— $5.6 $— Cross-currency swaps— 98.5 — — 46.8 — Interest rate swap agreements— 30.4 — — 22.6 — Total liabilities$— $134.5 $— $— $75.0 $— Measured at fair value on a non-recurring basis:Assets:Contingent consideration(1) $— $— $— $— $— $34.5 Goodwill(2)— — 5.0 — — — Assets held for sale, net(3)— — 12.8 — — — Total assets$— $— $17.8 $— $— $34.5 (1) During the year ended December 31, 2024, contingent consideration was recognized as a result of the divestiture of the Rare Diseases Business.(2) During the three months ended March 29, 2025, goodwill within the Richard Bittner Business with a carrying value of $6.2 million was written down to a fair value of $5.0 million.(3) We measured the net assets held for sale for impairment purposes and recorded a total impairment of $1.9 million, resulting in a net asset held for sale balance of $12.8 million (refer to Note 3).

15

Perrigo Company plc - Item 1Note 9

There were no